SCHEMBL4886101

SCHEMBL4886101

O=C(N/N=C(\C=N/O)c1cccc(Cl)c1)c1cccc(Br)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
ALDH1A1 P00352 5/20 0.50
OGG1 O15527 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2C19 P33261 2/20 0.50
MTOR P42345 3/20 0.48
CTSL P07711 1/20 0.48
RAB9A P51151 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NPC1 O15118 2/20 0.48
KMT2A Q03164 2/20 0.47
CCR6 P51684 1/20 0.47
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.46
GAA P10253 1/20 0.46
MEN1 O00255 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
AGTR1 P30556 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4903094 1.00 MAPT (0.50) MAPTALDH1A1OGG1CYP1A2CYP3A4
SCHEMBL4886109 1.00 MAPT (0.50) MAPTALDH1A1OGG1CYP1A2CYP3A4
SCHEMBL4903099 1.00 MAPT (0.50) MAPTALDH1A1OGG1CYP1A2CYP3A4
SCHEMBL4874999 0.93 MAPT (0.47) MAPTALDH1A1OGG1CYP1A2CYP3A4
SCHEMBL4875002 0.93 MAPT (0.47) MAPTALDH1A1OGG1CYP1A2CYP3A4
SCHEMBL2907122 0.92 MAPT (0.53) MAPTALDH1A1CYP1A2CYP3A4RAB9A
SCHEMBL2907123 0.92 MAPT (0.53) MAPTALDH1A1CYP1A2CYP3A4RAB9A
SCHEMBL4912706 0.90 CYP1A2 (0.53) MAPTALDH1A1OGG1CYP1A2CYP3A4
SCHEMBL4912712 0.90 CYP1A2 (0.53) MAPTALDH1A1OGG1CYP1A2CYP3A4
SCHEMBL4890013 0.87 MAPT (0.57) MAPTALDH1A1CYP1A2CYP3A4RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227787-A1 Use of New Lipoxygenase Inhibitors BIOLIPOX AB (SE) 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227787-A1 Use of New Lipoxygenase Inhibitors ALOX15, ALOX15B, ALOX12 MAPT 4603/4885ALDH1A1 464/4885OGG1 1846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.